Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults

AIDS

Volumn 25, Issue 11, 2011, Pages 1395-1403

  Jaffe, Harold W ^a,e   De Stavola, Bianca L ^b   Carpenter, Lucy M ^c   Porter, Kholoud ^d   Cox, David R ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NUFFIELD COLLEGE   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HAART; immune reconstitution inflammatory syndrome; Kaposi sarcoma; non Hodgkin lymphoma

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTORS; SARCOMA, KAPOSI; YOUNG ADULT;

EID: 79959994653     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283489c8b     Document Type: Article

References (23)

1. Shelburne S, Hamill R, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81:213-227. (Pubitemid 34507208)
2. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251-261.
3. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-1896. (Pubitemid 27500974)
4. Connick E, Kane MA, White IE, Ryder J, Campbell TR. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-1855. (Pubitemid 39657269)
5. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDs 2005; 19: 635-644. (Pubitemid 41527674)
6. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome. Risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46:456-462. (Pubitemid 350098697)
7. Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J Periodontol 2008; 79:362-368.
8. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 22:5224-5228. (Pubitemid 46224033)
9. Letang E, Almeida JM, Miro JM, Ayala E, White IE, Carrilho C, et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr 2010; 53:589-597.
10. Knysz B, Kuliszkiewicz-Janus M, Jelen M, Podlasin R, Gladysz A. Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients. Postepy Hig Med Dosw (Online) 2006; 60:547-551.
11. Huhn GD, Badri S, Vibhakar S, Tverdek F, Crank C, Lubelcheck R, et al. Early development of non-Hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIVinfected patients: implications for immune reconstitution. AIDS Res Ther 2010; 7:44-51.
12. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
13. Lennox JL, Dejesus E, Lazzarin A, Pollard RB, Madruga JVR, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:794-806.
14. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. http://www.who.int/hiv/pub/2010progressreport/ en/index.html. [Accessed 20 December 2010]
15. CASCADE. Concerted Action on SeroConversion to AIDS and Death in Europe. http://www.cascade-collaboration.org/. [Accessed 1 November 2010] .
16. Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy: the CASCADE collaboration-a collaboration of 23 cohort studies. PLoS Med 2010; 7:e10000239.
17. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993.
18. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens. Part B: Biological agents. Lancet Oncol 2009; 10:321-322.
19. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102:1-9.
20. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516-523. (Pubitemid 352005824)
21. Pallella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
22. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illness occurring after initiation of potent antiretroviral therapy. The Swiss HIV cohort study. JAMA 1999; 282:2220-2226. (Pubitemid 30002965)
23. Lawn SD, Myer L, Bekker L-G, Wood R. Tuberculosisassociated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341. (Pubitemid 46175045)